Communiqués Aileron Therapeutics, Inc.

Actions

ALRN

US00887A2042

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
2,99 ^USD	-3,24 %		-2,29 %	-1,92 %

16/05	Aileron Therapeutics, Inc. annonce des changements au sein de sa direction	CI
15/05	Aileron Therapeutics, Inc. annonce ses résultats pour le premier trimestre terminé le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Aileron Therapeutics to be Included in the Russell Microcap® Index	01/07	PR
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	15/05	AQ
Aileron Therapeutics to Present at Two Upcoming Investor Conferences	06/05	AQ
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million	03/05	AQ
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million	01/05	AQ
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)	01/05	AQ
Aileron Therapeutics : Corporate Presentation April 2024	15/04	PU
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	15/04	AQ
Aileron Therapeutics : Management Change/Compensation - Form 8-K	29/03	PU
Aileron Therapeutics Announces CEO Transition	12/03	AQ
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event	15/02	AQ
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024	01/02	AQ
Aileron Therapeutics : Merger Announcement	31/10/23	PU
Aileron Therapeutics Announces Acquisition of Lung Therapeutics	31/10/23	PR
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	08/05/23	AQ
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	20/03/23	AQ
AILERON THERAPEUTICS INC : Costs Associated with Exit or Disposal Activities, Other Events (form 8-K)	23/02/23	AQ
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives	21/02/23	AQ
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements	30/11/22	AQ
AILERON THERAPEUTICS INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	10/11/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Aileron Therapeutics, Inc.

Actions

ALRN

US00887A2042

Communiqués

Filtres